WELIREG is already approved by the FDA for the treatment of von Hippel-Lindau (VHL) disease and advanced renal cell carcinoma. The drug generated annual sales of $509 million in 2024, compared to ...

Welireg (belzutifan), an oral HIF-2 alpha inhibitor, has been approved by the UK drugs regulator the MHRA for VHL since May 2022. MSD acquired it as part of its $2.2 billion takeover of Peloton ...

Selling, general and administrative expenses were $2.6 billion in the first quarter, Merck noted, an increase of 3% compared with the first quarter of 2024. The increase was primarily due to higher ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.

Merck maintained its 2025 full-year revenue guidance of $64.1 billion to $65.6 billion, representing 1% to 3% growth excluding foreign exchange impacts. EPS guidance was adjusted to $8.82 to $8.97, ...

Sales of new drug Welireg are likely to have benefited from ... Investors will be keen to know the sales numbers of Capvaxive, which was approved in the European Union toward the end of March.

Sales of WELIREG increased 63% ... Dean Li, President of Research Labs, indicated no changes in approval timelines for upcoming filings. Analysts expressed concerns about GARDASIL inventory ...

Welireg was approved for relapsed or refractory advanced RCC previously treated with PD-1/L1 and VEGF-targeted therapies last year.

Merck MRK will report its first-quarter 2024 earnings on April 24, before market open. The Zacks Consensus Estimate for first ...